Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Sockolosky, Jonathan T ^a,b   Kivimäe, Saul ^a   Szoka, Francis C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN; CELL ADHESION MOLECULE; FC RECEPTOR; FC RECEPTOR, NEONATAL; FCGBP PROTEIN, HUMAN; FLUORESCENT DYE; HLA ANTIGEN CLASS 1; PROTEIN BINDING;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; ESCHERICHIA COLI; GEL PERMEATION CHROMATOGRAPHY; IN VIVO STUDY; INHIBITION KINETICS; LIGAND BINDING; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH MEASUREMENT; PLASMA HALF LIFE; PROTEIN BINDING; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; DOG; GENETICS; HALF LIFE TIME; HUMAN; MDCK CELL LINE; METABOLISM; PH; RAT;

ANIMALS; CELL ADHESION MOLECULES; DOGS; ESCHERICHIA COLI; FLUORESCENT DYES; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; MADIN DARBY CANINE KIDNEY CELLS; MICE; PROTEIN BINDING; RATS; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS;

EID: 84904816388     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102566     Document Type: Article

References (30)

1. Aggarwal RS (2014) What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 32: 32-39.
2. Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22: 868-876.
3. Alconcel SNS, Baas AS, Maynard HD (2011) FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym Chem 2: 1442.
4. Schellenberger V, Wang C-W, Geething NC, Spink BJ, Campbell A, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27: 1186-1190.
5. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, et al. (2013) Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. doi:10.3109/07388551.2013.834293.
6. Gehlsen K, Gong R, Bramhill D, Wiersma D, Kirkpatrick S, et al. (2012) Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs 4: 466-474.
7. Ying T, Chen W, Gong R, Feng Y, Dimitrov DS (2012) Soluble Monomeric IgG1 Fc. J Biol Chem 287: 19399-19408.
8. Ishino T, Wang M, Mosyak L, Tam A, Duan W, et al. (2013) Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J Biol Chem 288: 16529-16537.
9. Sleep D, Cameron J, Evans LR (2013) Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta 1830: 5526-5534.
10. Ober RJ, Martinez C, Lai X, Zhou J, Ward ES (2004) Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A 101: 11076-11081. (Pubitemid 38989586)
11. Prabhat P, Gan Z, Chao J, Ram S, Vaccaro C, et al. (2007) Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci 104: 5889-5894. (Pubitemid 47175629)
12. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725. (Pubitemid 47327396)
13. Hutt M, Färber-Schwarz A, Unverdorben F, Richter F, Kontermann RE (2012) Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem 287: 4462-4469.
14. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, et al. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277: 35035-35043.
15. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, et al. (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 21: 283-288.
16. DeLano WL, Ultsch MH, de Vos AM, Wells JA (2000) Convergent solutions to binding at a protein-protein interface. Science 287: 1279-1283. (Pubitemid 30112152)
17. Sockolosky JT, Tiffany MR, Szoka FC (2012) Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A 109: 16095-16100.
18. Dennis MS, Lowman HB, DeLano WL (2009) Methods and compositions for prolonging elimination half-times of bioactive compounds. U.S. Patent 7,635,749, filed September 26, 2006.
19. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, et al. (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18: 1759-1769. (Pubitemid 44884038)
20. Sockolosky JT, Szoka FC (2013) Periplasmic production via the pET expression system of soluble, bioactive human growth hormone. Protein Expr Purif 87: 129-135.
21. Shcherbo D, Merzlyak EM, Chepurnykh T V, Fradkov AF, Ermakova G V, et al. (2007) Bright far-red fluorescent protein for whole-body imaging. Nat Methods 4: 741-746. (Pubitemid 47338169)
22. Ober RJ, Radu CG, Ghetie V, Ward ES (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13: 1551-1559. (Pubitemid 33133882)
23. Kronvall G, Grey HM, Williams RC (1970) Protein A reactivity with mouse immunoglobulins. Structural relationship between some mouse and human immunoglobulins. J Immunol 105: 1116-1123.
24. Sakamoto K, Ito Y, Hatanaka T, Soni PB, Mori T, et al. (2009) Discovery and characterization of a peptide motif that specifically recognizes a non-native conformation of human IgG induced by acidic pH conditions. J Biol Chem 284: 9986-9993.
25. Mezo AR, McDonnell KA, Hehir CAT, Low SC, Palombella VJ, et al. (2008) Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci U S A 105: 2337-2342. (Pubitemid 351520514)
26. Vaccaro C, Zhou J, Ober RJ, Ward ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23: 1283-1288. (Pubitemid 41486856)
27. Patel D a, Puig-Canto A, Challa DK, Perez Montoyo H, Ober RJ, et al. (2011) Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol 187: 1015-1022.
28. Getman KE, Balthasar JP (2005) Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J Pharm Sci 94: 718-729. (Pubitemid 40577305)
29. Proetzel G, Roopenian DC (2014) Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 65: 148-153.
30. Wang X, Lupardus P, Laporte SL, Garcia KC (2009) Structural biology of shared cytokine receptors. Annu Rev Immunol 27: 29-60.